These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 27121947)

  • 1. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
    Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
    Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
    Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
    PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb repressive complex 2 in an autoinhibited state.
    Bratkowski M; Yang X; Liu X
    J Biol Chem; 2017 Aug; 292(32):13323-13332. PubMed ID: 28607149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
    Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
    Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
    Jiao L; Liu X
    Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone methylation by PRC2 is inhibited by active chromatin marks.
    Schmitges FW; Prusty AB; Faty M; Stützer A; Lingaraju GM; Aiwazian J; Sack R; Hess D; Li L; Zhou S; Bunker RD; Wirth U; Bouwmeester T; Bauer A; Ly-Hartig N; Zhao K; Chan H; Gu J; Gut H; Fischle W; Müller J; Thomä NH
    Mol Cell; 2011 May; 42(3):330-41. PubMed ID: 21549310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor.
    Diehl KL; Ge EJ; Weinberg DN; Jani KS; Allis CD; Muir TW
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22152-22157. PubMed ID: 31611394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
    Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
    Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the polycomb protein EED in the propagation of repressive histone marks.
    Margueron R; Justin N; Ohno K; Sharpe ML; Son J; Drury WJ; Voigt P; Martin SR; Taylor WR; De Marco V; Pirrotta V; Reinberg D; Gamblin SJ
    Nature; 2009 Oct; 461(7265):762-7. PubMed ID: 19767730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of automethylated PRC2 by dimerization on chromatin.
    Sauer PV; Pavlenko E; Cookis T; Zirden LC; Renn J; Singhal A; Hunold P; Hoehne-Wiechmann MN; van Ray O; Kaschani F; Kaiser M; Hänsel-Hertsch R; Sanbonmatsu KY; Nogales E; Poepsel S
    Mol Cell; 2024 Oct; 84(20):3885-3898.e8. PubMed ID: 39303719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).
    Xu C; Bian C; Yang W; Galka M; Ouyang H; Chen C; Qiu W; Liu H; Jones AE; MacKenzie F; Pan P; Li SS; Wang H; Min J
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19266-71. PubMed ID: 20974918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
    Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
    Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.
    Antonysamy S; Condon B; Druzina Z; Bonanno JB; Gheyi T; Zhang F; MacEwan I; Zhang A; Ashok S; Rodgers L; Russell M; Gately Luz J
    PLoS One; 2013; 8(12):e84147. PubMed ID: 24367637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes.
    Poepsel S; Kasinath V; Nogales E
    Nat Struct Mol Biol; 2018 Feb; 25(2):154-162. PubMed ID: 29379173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.